DRUG TREATMENT: MAXIMISING BENEFIT AND MINIMISING RISK*

1 Grodstein F MJ Stampfer Manson JE Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-61.

2 Grodstein F JE Manson Colditz GA A prospective observational study of postmenopausal hormone replacement therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133:933-41.

3 Baber RJ JL O’Hara Boyle FM. Hormone replacement therapy: to use or not to use? Med J Aust 2003; 178:630-3.

4Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.

5Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 1995;48:1441-52.

6 Caro J W Klittich McGuire A The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82.

7 Salomon JA MC Weinstein Hammitt JK Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156:761-73.

8 Weinstein MC SJ Goldie Losina E Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.

9 Kim JJ TC Wright Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002; 287:2382-90.

10(http://www.fda.gov/oc/tfrm/riskmanagement.pdf)

11(http://www.fda.gov/cder/meeting/riskmanagement)

12 Sonnenblick EH. Cardiorenal differences among NSAIDs and coxibs: real-world experience. Am J Manag Care 2002; 8:5369-70.

13Prescription Medicines Data File Documentation. Third National Health and Nutrition Examination Survey (NHANES III), 1988-94. Series II, No. 2A. 1998.

14 Lazarou J BH Pomeranz Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.

15(http://www.hm-treasury.gov. uk/Consultations _and_Legislation/wanless/consult_wanless_final.cfm)

16 Taxis K Barber N. Ethnographic study of incidence and severity of intravenous drug errors. BMJ 2003; 326:684.

17DOH. An organisation with a memory. Norwich: The Stationery Office; 2000. (http://www.doh.gov.uk/cmo/progress/patientsafety/patientsafety2.htm)

18Scottish Executive Health Department. Learning from experience. How to improve safety for patients in Scotland. 2002. (http://www.cdc.gov/nchs/data/nhanes/nhanes3/PUPREMED-acc.pdf)